What is HC Wainwright’s Estimate for ORIC Q1 Earnings?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Oric Pharmaceuticals in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.85) EPS.

Several other research firms have also commented on ORIC. Citigroup dropped their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $19.45.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $13.62 on Tuesday. The company’s fifty day moving average price is $10.24 and its 200-day moving average price is $10.47. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.93. The firm has a market capitalization of $1.41 billion, a PE ratio of -10.09 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02).

Institutional Trading of Oric Pharmaceuticals

Institutional investors have recently modified their holdings of the business. E Fund Management Co. Ltd. purchased a new stake in shares of Oric Pharmaceuticals in the second quarter valued at $139,000. BlackRock Inc. purchased a new stake in Oric Pharmaceuticals during the 2nd quarter worth about $73,904,000. Deutsche Bank AG acquired a new position in Oric Pharmaceuticals in the 2nd quarter valued at about $800,000. Bank of New York Mellon Corp acquired a new position in Oric Pharmaceuticals in the second quarter valued at $2,383,000. Finally, Defilade Capital Management L.P. acquired a new position in Oric Pharmaceuticals during the first quarter worth approximately $10,680,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.